Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Change in Cash (2019 - 2025)

Historic Change in Cash for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $100.9 million.

  • Harmony Biosciences Holdings' Change in Cash rose 4406.67% to $100.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $259.6 million, marking a year-over-year increase of 31353.21%. This contributed to the annual value of $141.3 million for FY2024, which is 10971.72% up from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Change in Cash stood at $100.9 million, which was up 4406.67% from $57.1 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Change in Cash ranged from a high of $100.9 million in Q3 2025 and a low of -$87.5 million during Q1 2021
  • Its 5-year average for Change in Cash is $22.0 million, with a median of $24.8 million in 2022.
  • As far as peak fluctuations go, Harmony Biosciences Holdings' Change in Cash plummeted by 28585.21% in 2021, and later skyrocketed by 87483.31% in 2024.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' Change in Cash stood at $44.6 million in 2021, then plummeted by 139.37% to -$17.6 million in 2022, then rose by 26.4% to -$12.9 million in 2023, then skyrocketed by 607.89% to $65.6 million in 2024, then soared by 53.81% to $100.9 million in 2025.
  • Its Change in Cash stands at $100.9 million for Q3 2025, versus $57.1 million for Q2 2025 and $36.0 million for Q1 2025.